The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1935
Publisher
MDPI AG
Online
2019-12-05
DOI
10.3390/cancers11121935
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
- (2019) Caroline E. Nunes-Xavier et al. Current Urology Reports
- Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis
- (2019) Zhen Chen et al. Cancer Management and Research
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
- (2019) Viktor Grünwald et al. Future Oncology
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
- (2019) Shuo Li et al. Cancer Management and Research
- Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program
- (2018) Ugo De Giorgi et al. BJU INTERNATIONAL
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
- (2018) Delia De Lisi et al. Expert Opinion on Drug Metabolism & Toxicology
- IL-1β promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway
- (2018) Aiwen Yu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis
- (2018) Seok-Soo Byun et al. JOURNAL OF SURGICAL ONCOLOGY
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-1β/IL-6 network in the tumor microenvironment of human colorectal cancer
- (2018) Guanglin Cui et al. PATHOLOGY RESEARCH AND PRACTICE
- Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
- (2018) Alberto Farolfi et al. Targeted Oncology
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
- (2018) Tao Wang et al. Cancer Discovery
- Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy
- (2018) Hironori Fukuda et al. Oncotarget
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
- (2018) Rana R. McKay et al. Cancer Immunology Research
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
- (2018) Hayriye Tatli Dogan et al. Diagnostic Pathology
- Role of systemic inflammatory response markers in urological malignancy
- (2018) Yoshio Ohno INTERNATIONAL JOURNAL OF UROLOGY
- A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
- (2018) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Kidney cancer: The next decade
- (2018) Samra Turajlic et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
- (2018) Kosuke Ueda et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
- (2018) Xian Shen et al. BMJ-British Medical Journal
- Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
- (2018) Han Yao et al. Frontiers in Immunology
- Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
- (2018) Peixin Dong et al. Frontiers in Oncology
- A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma
- (2018) Yiting Geng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer
- (2018) Ella Grilz et al. THROMBOSIS AND HAEMOSTASIS
- Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
- (2017) Yosuke Yasuda et al. International Journal of Clinical Oncology
- Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection
- (2017) Sen Li et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers.
- (2017) Ghayathri Jeyakumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2.
- (2017) Martin Henner Voss et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression pattern of immune checkpoint–associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
- (2017) Takuto Hara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- (2017) Jun Teishima et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy
- (2017) Jiwei Huang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review
- (2017) Romain Boissier et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis
- (2017) Jie-Hui Zhong et al. Oncotarget
- Prognostic value of neutrophil-to-lymphocyte ratio in urothelial carcinoma of the upper urinary tract and bladder: a systematic review and meta-analysis
- (2017) Xintao Li et al. Oncotarget
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- (2017) Ghayathri Jeyakumar et al. Journal for ImmunoTherapy of Cancer
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy
- (2016) Qi Qi et al. CANCER
- Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
- (2016) Francesca Tartari et al. CANCER TREATMENT REVIEWS
- A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent
- (2016) Nathan Grimes et al. Clinical Genitourinary Cancer
- An Overview of Emerging Immunotargets of Genitourinary Tumors
- (2016) Rodolfo Montironi et al. CURRENT DRUG TARGETS
- Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival
- (2016) Steffen Rausch et al. INTERNATIONAL JOURNAL OF UROLOGY
- The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker
- (2016) Anne Helene Køstner et al. JOURNAL OF SURGICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
- (2016) Mahmoud Abbas et al. MEDICAL ONCOLOGY
- Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies
- (2016) Tian Zhang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Onodera's Prognostic Nutritional Index as an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
- (2016) Matthew S. Broggi et al. UROLOGY
- Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients
- (2016) Hong Hu et al. WORLD JOURNAL OF UROLOGY
- Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
- (2016) Alessandro Passardi et al. Oncotarget
- Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor
- (2016) Minyong Kang et al. Oncotarget
- Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- (2016) Cristian Lolli et al. Oncotarget
- Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma
- (2016) Dae Sung Cho et al. Scandinavian Journal of Urology
- Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Renal Cell Carcinoma Patients Undergoing Nephrectomy
- (2015) Hwang Gyun Jeon et al. ANNALS OF SURGICAL ONCOLOGY
- Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer
- (2015) Seyda Gunduz et al. Asia-Pacific Journal of Clinical Oncology
- PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
- (2015) Katia R M Leite et al. Diagnostic Pathology
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- (2015) S.-J. Shin et al. ONCOLOGIST
- Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
- (2015) Matteo Santoni et al. Targeted Oncology
- The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma
- (2015) Sebastian L. Hofbauer et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma
- (2015) Ilaria Lucca et al. WORLD JOURNAL OF UROLOGY
- Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis
- (2015) K. Hu et al. BMJ Open
- PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
- (2015) R. W. Joseph et al. Cancer Immunology Research
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study
- (2014) A. C. Vidal et al. CLINICAL CANCER RESEARCH
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy
- (2014) Boyd R. Viers et al. EUROPEAN UROLOGY
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer
- (2014) Ugo De Giorgi et al. Journal of Geriatric Oncology
- Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy
- (2014) Yong Park et al. SpringerPlus
- Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)
- (2013) Michela de Martino et al. BJU INTERNATIONAL
- High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
- (2013) M Pichler et al. BRITISH JOURNAL OF CANCER
- Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
- (2013) M Santoni et al. BRITISH JOURNAL OF CANCER
- NSAIDs Inhibit Tumorigenesis, but How?
- (2013) Evrim Gurpinar et al. CLINICAL CANCER RESEARCH
- Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies
- (2013) Toni K. Choueiri et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status
- (2013) Yoshio Ohno et al. International Journal of Clinical Oncology
- Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma
- (2013) Michela de Martino et al. JOURNAL OF UROLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)
- (2012) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?
- (2012) Bulent Cetin et al. Clinical Genitourinary Cancer
- Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma
- (2012) Sunil Saroha et al. JOURNAL OF UROLOGY
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
- (2012) Peter M Rothwell et al. LANCET
- The Role of the Systemic Inflammatory Response as a Biomarker in Immunotherapy for Renal Cell Cancer
- (2012) Sara Ramsey Molecular Diagnosis & Therapy
- Non-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective Cohort
- (2011) Elizabeth H Ruder et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer
- (2011) Eunyoung Cho ARCHIVES OF INTERNAL MEDICINE
- Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems
- (2011) G W A Lamb et al. BRITISH JOURNAL OF CANCER
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
- (2011) Eric Tartour et al. CANCER AND METASTASIS REVIEWS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
- (2011) Daniel Keizman et al. EUROPEAN JOURNAL OF CANCER
- The Epidemiology of Renal Cell Carcinoma
- (2011) Börje Ljungberg et al. EUROPEAN UROLOGY
- Prognostic Significance of Body Mass Index in Asian Patients With Localized Renal Cell Carcinoma
- (2011) Kazumasa Komura et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study
- (2010) M J Proctor et al. BRITISH JOURNAL OF CANCER
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Dual Roles for Immunity in Gastrointestinal Cancers
- (2010) Cristina Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma
- (2010) Yoshio Ohno et al. JOURNAL OF UROLOGY
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
- (2010) Peter M Rothwell et al. LANCET
- Epidemiology and risk factors for kidney cancer
- (2010) Wong-Ho Chow et al. Nature Reviews Urology
- Prognostic factors in renal cell carcinoma
- (2010) Alessandro Volpe et al. WORLD JOURNAL OF UROLOGY
- Chemopreventive Efficacy of Naproxen and Nitric Oxide-naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers
- (2009) V. E. Steele et al. Cancer Prevention Research
- EORTC-GU group expert opinion on metastatic renal cell cancer
- (2009) Theo M. de Reijke et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
- (2008) Jin F. Li et al. BJU INTERNATIONAL
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
- (2008) Robert J. Motzer et al. CANCER
- Brain metastasis from renal cell carcinoma
- (2008) Brian Shuch et al. CANCER
- Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma
- (2008) Scott E. Eggener et al. JOURNAL OF UROLOGY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now